secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115223
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q3: DEXTENZA revenue up 26% YoY to $15M; net loss narrows to $0.5M
--------------------------------------------------------------------------------

- DEXTENZA net product revenue $15.0M (+26% vs Q3 2022), in line with Q2 2023; full-year guidance raised to upper end of $55-60M.
- Net loss improved to $(0.5M) or $(0.01) per basic share vs $(24.2M) loss in Q3 2022; diluted EPS $(0.25).
- FDA agreed under Special Protocol Assessment to pivotal SOL trial for AXPAXLI (wet AMD); first patient dosing expected by year-end.
- Cash and cash equivalents $110.6M as of Sept 30, 2023; management believes sufficient to fund operations into 2025.
- Top-line data from HELIOS trial (NPDR) expected Q2 2024; Phase 2 data for OTX-TIC (glaucoma) expected April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/0001104659-23-115223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/tm2329748d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer